Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens

Stephens downgraded Akoya Biosciences (AKYA) to Equal Weight from Overweight with a price target of $1.80, down from $3.50, given the pending acquisition by Quanterix (QTRX). If the deal is closed as proposed in Q2, it would represent an attractive return on Akoya shares based on current prices, the analyst tells investors.